Genmab — December 2016
-
According to a recent update, the Genmab’s Datarumumab has yielded very positive results, which are even comparable in performance to Pharmacokinetics of Intravenous injections. The results have put Revlimid in some very serious trouble as the analyst believes that the other drug is better in almost all three areas, namely efficacy, safety and convenience.
-
Og Arzerra er ikke helt død. http://medwatch.dk/Medicinal___Biotek/article9207667.ece
-
Short Interest Worth Mentioning: GENMAB A/S ORD (OTCMKTS:GNMSF) Can’t Be More Risky. Short Interest Increasedhttp://www.kentuckypostnews.com/2016/12/06/short-interest-worth-mentioning-genmab-as-ord-otcmktsgnmsf-cant-be-more-risky-short-interest-increased/
-
Ok..Tak jkj.
-
Det vil sige at der er åbnet shorts for 38.000 oven i de 301.000 vi har haft siden maj 2016.
-
Det er peanuts.
-
38.000 aktier.
-
Det har vi set de seneste dage.
-
Linket fra jkj indeholder den bedste salgstale jeg længe har set i kommentatorsporet, nok skrevet af en hollænder, måske en fra eller omkring den gruppe som var sikker på Genmab skulle sælges. Han mener Celgene skal købe dette undervurderede selskab lige nu.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind